After waking up from the procedure, he told me he could take full breaths for the first time in years,” Dr. Mark Sigler said ...

Physicians recommend that patients with chronic obstructive pulmonary disease (COPD) quit smoking and use steroids, ...

"We hope this research will pave the way for new treatment options for COPD patients, but first we need to continue to analyze and validate the results in larger and more comprehensive studies.

Ensifentrine is a promising supplementary therapeutic option in the management of chronic obstructive pulmonary disease (COPD), according to systematic review and meta-analysis findings published in ...

Ohtuvayre showed significant improvement in lung function by 12 weeks. Follow-up analyses showed that Ohtuvayre had long-term ...

AstraZeneca’s respiratory and immunology portfolio is driving significant growth, with R&I assets forecasted to account for ...

The growing prevalence of COPD among women can be attributed to a combination of biological, environmental, and societal ...

COPD is the third leading cause of death worldwide but treatment for the condition is stuck in the 20th century. We need to provide these patients with life-saving options before their time runs out.

But Verona is off to a strong start as Ohtuvayre generated sales of $42 million in 2024, the company reported on Tuesday.

Conclusion. In the treatment of COPD exacerbations, systemic corticosteroids improve airflow limitations, decrease treatment failure rates, decrease the risk of relapse, and may improve symptoms ...

Nov. 27, 2024 — A recent trial finds an injection given during some asthma and COPD attacks is more effective than the current treatment of steroid tablets, reducing the need for further ...

Chief executive David Zaccardelli said Ohtuvayre was off to an "exceptionally strong start," with more than 3,500 healthcare ...